Doxorubicin, cyclophosphamide, and 5-fluorouracil in patients with carcinoma of the cervix or vagina.
Thirty-six evaluable patients with carcinoma of the uterine cervix or vagina not amenable to surgery or radiation therapy were treated with doxorubicin, cyclophosphamide, and 5-fluorouracil; 16.5% of the patients responded, with 2.7% having a complete response. Only four (11.17%) of the 36 patients are alive, all with persistent malignancy, and none of the responders are alive. Because of the low response and survival rates, this combination is not recommended for women with recurrent cervical or vaginal carcinoma.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014625:Vaginal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil